Bone Loss Treatment From Adjuvant Zoledronate Efficacy — BLAZE  

Breast Neoplasms Clinical Trial

Official title: An Open,Multicentre,Prospective Study of Adjuvant Zoledronate Treatment in Osteoporosis Women With Breast Cancer

Status Terminated

Clinical Trial Summary

The main purpose of this study is to observe and assess the impact of adjuvant zoledronate on bone density in breast cancer patients.

The second purposes:

• The efficacy of adjuvant zoledronate

• The safety of adjuvant zoledronate

• The bone loss of breast cancer patients in Guangdong

• The correlation between bone loss of breast cancer patients and treatment of disease in Guangdong

Clinical Trial Description

Breast cancer is the most commonly diagnosed malignant disease and the leading cause of cancer-related mortality among women.

Zoledronate is a bone-targeted bisphosphonate, which is used to treat osteoporosis and to reduce the risk of skeletal morbidity in patients with bone metastases. Zoledronate can also reduce the persistence of disseminated tumour cells in the bone marrow of women with early-stage breast cancer. Nowadays, consensus is emerging that certain subsets of patients with early-stage breast cancer may benefit from bisphosphonate therapy. ;

Related Conditions & MeSH terms

• Bone Loss
• Breast Neoplasms

• NCT number: NCT01623908
• Study type: Interventional
• Source: First Affiliated Hospital, Sun Yat-Sen University
• Status: Terminated
• Phase: N/A
• Start date: July 2011
• Completion date: June 2013